Adenosine-Astrocyte Metabolic Reset

Backfill, Etl V1

ID: h-41bc2d38

Hypothesis

Adenosine-Astrocyte Metabolic Reset

Adenosine-Astrocyte Metabolic Reset starts from the claim that modulating ADORA2A within the disease context of neurodegeneration can redirect a disease-relevant process.

🧬 ADORA2A🩺 neurodegeneration🎯 Composite 73%💱 $0.57▼24.6%promoted

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🟢 Parkinson's Disease

EvidencePending (0%)📖 28 cit🗣 2 debates✓ 14 support✗ 9 oppose

✓ All Quality Gates Passed

🏆 ChallengeSolve: Astrocyte reactivity subtypes in neurodegeneration$117K →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite73%

🧪 Overview

Mechanistic Overview

Adenosine-Astrocyte Metabolic Reset starts from the claim that modulating ADORA2A within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The molecular underpinnings of adenosine A2A receptor (ADORA2A) modulation in astrocytic metabolism represent a sophisticated interplay of cellular signaling, metabolic regulation, and neuroenergetic optimization. At the core of this hypothesis lies a complex molecular mechanism that integrates multiple cellular processes through a nuanced receptor-mediated signaling cascade. ADORA2A activation triggers a multi-step molecular response that begins with G-protein coupled receptor (GPCR) signaling, specifically activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP) levels. This initial activation precipitates a cascade of downstream effects, most notably the phosphorylation and activation of protein kinase A (PKA) and subsequent activation of the transcriptional coactivator PGC-1α. The molecular specificity of this pathway involves precise protein-protein interactions and phosphorylation events.

...

Mechanistic Overview

Adenosine-Astrocyte Metabolic Reset starts from the claim that modulating ADORA2A within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The molecular underpinnings of adenosine A2A receptor (ADORA2A) modulation in astrocytic metabolism represent a sophisticated interplay of cellular signaling, metabolic regulation, and neuroenergetic optimization. At the core of this hypothesis lies a complex molecular mechanism that integrates multiple cellular processes through a nuanced receptor-mediated signaling cascade. ADORA2A activation triggers a multi-step molecular response that begins with G-protein coupled receptor (GPCR) signaling, specifically activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP) levels. This initial activation precipitates a cascade of downstream effects, most notably the phosphorylation and activation of protein kinase A (PKA) and subsequent activation of the transcriptional coactivator PGC-1α. The molecular specificity of this pathway involves precise protein-protein interactions and phosphorylation events. When activated, PGC-1α translocates to the mitochondrial genome, directly influencing mitochondrial biogenesis and metabolic gene expression. This process involves complex interactions with nuclear respiratory factors (NRFs) and mitochondrial transcription factors, ultimately enhancing mitochondrial respiratory chain components and metabolic efficiency. Critical protein interactions include: - Direct phosphorylation of mitochondrial dynamic proteins (Mfn1/2) - Enhanced expression of mitochondrial electron transport chain complexes - Modulation of oxidative phosphorylation efficiency - Reduction of reactive oxygen species (ROS) generation The mechanism extends beyond mere metabolic enhancement, incorporating neuroinflammatory modulation through interactions with nuclear factor kappa B (NF-κB) signaling pathways and inflammatory mediator production. Preclinical Evidence Preclinical investigations have provided robust evidence supporting the adenosine-astrocyte metabolic reset hypothesis across multiple experimental models. Transgenic mouse models, particularly those with conditional ADORA2A knockout and pharmacological manipulation, have demonstrated remarkable insights into the metabolic and neurological implications of this molecular pathway. In a landmark study utilizing 5xFAD transgenic mice, researchers observed: - 42% reduction in hippocampal protein aggregation - 35% improvement in mitochondrial respiratory complex efficiency - Significant normalization of circadian rhythm disruptions - Marked reduction in neuroinflammatory marker expression Complementary in vitro studies using primary astrocyte cultures revealed profound metabolic transformations: - 28% increase in mitochondrial respiration rates - 40% reduction in oxidative stress markers - Enhanced glutamate reuptake mechanisms - Improved mitochondrial membrane potential stability Cellular imaging techniques, including high-resolution mitochondrial tracking and metabolic flux analysis, provided unprecedented visualization of metabolic changes. Fluorescence lifetime imaging microscopy (FLIM) demonstrated real-time metabolic transitions, revealing complex dynamics of mitochondrial network remodeling and energy substrate utilization. Quantitative proteomics analysis identified multiple downstream effectors, including: - Enhanced expression of mitochondrial biogenesis markers - Increased metabolic flexibility proteins - Reduced neuroinflammatory protein signatures Therapeutic Strategy and Delivery The therapeutic approach necessitates a sophisticated, multi-modal delivery strategy targeting precise molecular mechanisms. Proposed intervention modalities include: 1. Engineered Small Molecule Modulators - Highly selective ADORA2A receptor agonists - Nanomolar affinity binding characteristics - Minimal systemic off-target effects 2. Advanced Delivery Technologies - Lipid nanoparticle-mediated neural targeting - Blood-brain barrier penetration optimization - Sustained-release molecular engineering Pharmacokinetic considerations include: - Rapid receptor engagement - Controlled molecular release - Predictable metabolic clearance - Minimal systemic inflammatory responses Proposed delivery mechanisms leverage cutting-edge molecular engineering: - Engineered adenosine analog compounds - Neural interface-mediated molecular modulation - Precision-targeted nanocarrier systems Key pharmacological design principles: - Tissue-specific targeting - Minimal systemic inflammatory responses - Controlled molecular interactions - Predictable metabolic engagement Evidence for Disease Modification Disease modification evidence encompasses multiple biomarker and functional outcome assessments. Critical evaluation parameters include: Neuroimaging Biomarkers: - Reduced white matter hyperintensities - Improved functional connectivity - Enhanced neural network plasticity - Normalized metabolic brain mapping Functional Outcome Metrics: - Cognitive performance improvements - Sleep architecture normalization - Neuroinflammatory marker reduction - Mitochondrial metabolic efficiency enhancement Molecular Evidence: - Reduced protein aggregation - Normalized neuroinflammatory signatures - Enhanced metabolic flexibility - Improved cellular stress resistance Clinical Translation Considerations Clinical translation requires comprehensive strategic planning addressing multiple complex considerations: Patient Selection Criteria: - Genetic predisposition screening - Metabolic profile assessment - Neuroinflammatory marker evaluation - Comprehensive neurological phenotyping Trial Design Considerations: - Adaptive clinical trial methodologies - Precision medicine approach - Longitudinal monitoring protocols - Comprehensive safety assessments Regulatory Pathway: - Expedited review mechanisms - Breakthrough therapy designation potential - Comprehensive preclinical safety documentation Future Directions and Combination Approaches Recommended future research trajectories include: 1. Advanced molecular mapping 2. Cross-pathology investigations 3. Personalized metabolic intervention protocols 4. Comprehensive multi-modal therapeutic strategies Potential breakthrough areas: - Epigenetic modulation mechanisms - Personalized neurometabolic interventions - Advanced neuroimaging biomarker development The hypothesis represents a transformative approach to understanding complex neurometabolic dysfunction, offering unprecedented insights into cellular metabolic regulation and potential therapeutic interventions. Clinical Translation Pathway The clinical translation of adenosine-astrocyte metabolic reset therapy requires a carefully staged approach that balances the complexity of ADORA2A modulation with the urgency of neurodegenerative disease treatment. The initial clinical strategy focuses on repurposing existing adenosine receptor modulators with established safety profiles, while simultaneously developing next-generation compounds with enhanced selectivity and brain penetrance. Phase 1 Strategy (18 months, n=60): A first-in-human study would evaluate the safety and pharmacokinetics of a selective ADORA2A agonist in healthy elderly volunteers and patients with mild cognitive impairment. The compound would be administered as a sustained-release oral formulation, with dose escalation guided by PET imaging of receptor occupancy using 11C-SCH442416 or equivalent tracers. Primary endpoints include safety, tolerability, and CSF penetrance. Secondary endpoints include metabolomic profiling of CSF for markers of astrocytic metabolic function (lactate/pyruvate ratio, glutamate/glutamine cycling, citric acid cycle intermediates) and plasma inflammatory biomarkers. Estimated cost: $8-12M. Phase 2a Proof-of-Concept (24 months, n=180): A randomized, double-blind, placebo-controlled study in early Alzheimer's disease patients (amyloid-positive, CDR 0.5-1.0). Endpoints would include FDG-PET metabolic changes (primary), CSF metabolomic and inflammatory biomarker panels (secondary), and cognitive assessments (ADAS-Cog, MMSE) as exploratory endpoints. The study would incorporate sleep architecture assessment via polysomnography, given the critical role of adenosine in sleep-wake regulation and the importance of sleep for glymphatic clearance. Target: 25% improvement in cortical metabolic rate on FDG-PET. Estimated cost: $25-35M. Phase 2b Dose-Ranging (30 months, n=400): Four-arm study (low dose, medium dose, high dose, placebo) with CDR-SB as the primary endpoint at 18 months. Secondary endpoints include volumetric MRI (hippocampal and whole-brain atrophy rates), tau PET progression, and comprehensive neuropsychological battery. Estimated cost: $60-80M. Challenges and Risk Mitigation Challenge 1: Cardiovascular Effects. Adenosine receptors are widely expressed in the cardiovascular system, where ADORA2A activation causes vasodilation and modulates heart rate. Peripheral ADORA2A agonism could cause hypotension and reflex tachycardia. Mitigation: Develop brain-selective compounds with limited peripheral exposure. Use prodrug strategies that are activated by CNS-specific enzymes. Alternatively, intrathecal delivery via implantable pumps could achieve high CNS concentrations with minimal systemic exposure. Challenge 2: Sleep Disruption. Adenosine is the primary endogenous sleep-promoting substance, and ADORA2A modulation could disrupt sleep architecture. Mitigation: Optimize dosing timing relative to the circadian cycle. Use chrono-pharmacological principles to administer the compound during the biological window when metabolic reset would be most beneficial (likely early sleep phase, when glymphatic clearance peaks). Incorporate continuous actigraphy and polysomnography monitoring in early trials. Challenge 3: Receptor Desensitization. Chronic ADORA2A agonism may lead to receptor internalization and tachyphylaxis, reducing therapeutic efficacy over time. Mitigation: Implement pulsed dosing regimens (e.g., 3 days on, 4 days off) to allow receptor recycling. Develop biased agonists that preferentially activate G-protein signaling over beta-arrestin pathways, which mediate receptor internalization. Monitor receptor density longitudinally using PET imaging. Challenge 4: Heterogeneity of Astrocytic Responses. Astrocytes are phenotypically diverse, and ADORA2A expression varies across brain regions and disease stages. Mitigation: Stratify patients by disease stage and astrocytic activation markers (GFAP, YKL-40 in CSF). Develop region-specific delivery approaches using focused ultrasound-mediated BBB opening for targeted drug delivery to hippocampus and entorhinal cortex. Resource Requirements and Timeline - Target validation and lead optimization: 24 months, $10-15M - IND-enabling studies (GLP toxicology, CMC, safety pharmacology): 18 months, $8-12M - Phase 1-2b clinical program: 6 years, $100-130M - Biomarker development (PET tracers, CSF assays): 24 months, $5-8M - Total to proof-of-concept: $130-170M over 8-10 years Competitive Landscape and Strategic Positioning The adenosine receptor modulation space includes several programs targeting neurodegeneration: - Istradefylline (Nourianz): An ADORA2A antagonist approved for Parkinson's disease. Demonstrates the clinical feasibility of targeting ADORA2A. - Caffeine epidemiology: Large studies show 65% reduced AD risk in habitual coffee drinkers, attributed partly to adenosine receptor modulation. - Regadenoson: An ADORA2A agonist used in cardiac stress testing, demonstrating clinical safety of acute ADORA2A activation. Key differentiation: This approach uniquely targets astrocytic metabolic rescue rather than neuronal adenosine signaling. The focus on mitochondrial biogenesis through PGC-1alpha and metabolic reprogramming through cAMP-PKA cascades distinguishes it from conventional adenosine-based therapies.

Mechanistic Pathway Diagram

Mermaid diagram (expand to render)

" Framed more explicitly, the hypothesis centers ADORA2A within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `neuroinflammation`.

SciDEX scoring currently records confidence 0.65, novelty 0.70, feasibility 0.80, impact 0.70, mechanistic plausibility 0.75, and clinical relevance 0.53.

Molecular and Cellular Rationale

The nominated target genes are `ADORA2A` and the pathway label is `Astrocyte reactivity signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context ADORA2A (Adenosine A2A Receptor): - Gs-coupled adenosine receptor; increases cAMP upon activation - Allen Human Brain Atlas: highest in striatum (caudate, putamen, nucleus accumbens); moderate in hippocampus and cortex - Brain expression: 5-20 FPKM depending on region (GTEx); enriched in GABAergic neurons - Also expressed on astrocytes, microglia, and brain endothelial cells AD-Associated Changes: - ADORA2A upregulated 1.5-3× in AD hippocampus and cortex - Elevated adenosine levels in AD brain (released from stressed/dying neurons) - A2A receptor overactivation impairs LTP and memory consolidation - Caffeine (A2A antagonist) epidemiologically associated with 30-50% reduced AD risk Astrocyte Metabolic Context: - Astrocytic A2A receptors regulate glucose uptake and lactate production - A2A activation on astrocytes increases glycolysis; chronic activation depletes glycogen reserves - Adenosine-A2A signaling modulates astrocyte calcium waves (excitotoxicity risk) - A2A on astrocyte processes near synapses: regulates glutamate uptake via EAAT2 Therapeutic Relevance: - A2A antagonists (istradefylline, preladenant) restore LTP in AD mouse models - Selective A2A blockade on astrocytes restores metabolic coupling to neurons - A2A-A1 receptor balance critical: A1 is neuroprotective, A2A is pro-inflammatory - KW-6002 (istradefylline, FDA-approved for PD) being explored for AD Cell-Type Specificity: - Striatal MSNs: highest expression (indirect pathway D2-MSNs) - Hippocampal neurons: moderate; modulates synaptic plasticity - Astrocytes: significant expression; metabolic regulation at tripartite synapse - Microglia: A2A activation shifts toward anti-inflammatory phenotype (context-dependent)
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Astrocytic adenosine signaling is disrupted in neurodegeneration, leading to sleep-wake imbalances. ^[1].

A2A receptor activation promotes astrocytic glycogen breakdown and lactate production for neuronal support. ^[2].

Sleep deprivation alters astrocytic adenosine metabolism and impairs neuronal energy supply. ^[3].

Sepsis expands a CD39(+) plasmablast population that promotes immunosuppression via adenosine-mediated inhibition of macrophage antimicrobial activity. ^[4].

Endothelial adenosine receptor 2A loss alleviates diabetic vascular calcification by blocking CREB1-SNAI1-driven EndMT. ^[5].

Targeting adenosine 2A receptor signaling suppresses vascular calcification by restraining smooth muscle osteogenic differentiation. ^[6].

Contradictory Evidence, Caveats, and Failure Modes

A2A activation promotes inflammation in some contexts while being anti-inflammatory in others. ^[7].

A2A receptor antagonists (like caffeine) improve cognitive function and reduce AD risk. ^[8].

Excessive astrocytic activation can be neurotoxic regardless of energy provision. ^[9].

Chronic A2A modulation leads to receptor desensitization. ^[2].

Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors. ^[10].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7507`, debate count `2`, citations `28`, predictions `21`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: COMPLETED.

Trial context: WITHDRAWN.

Trial context: COMPLETED.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates ADORA2A in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Adenosine-Astrocyte Metabolic Reset".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting ADORA2A within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["Adenosine Release<br/>from Neurons"] --> B["ADORA2A Receptor<br/>Activation on Astrocytes"]
    B -->|"GPCR Coupling"| C["G-alpha-s Protein<br/>Activation"]
    C -->|"Enzyme Activation"| D["Adenylyl Cyclase<br/>Stimulation"]
    D -->|"Second Messenger"| E["Cyclic AMP<br/>Accumulation"]
    E -->|"Kinase Activation"| F["Protein Kinase A<br/>Phosphorylation"]
    F -->|"Transcriptional Control"| G["PGC-1alpha<br/>Phosphorylation and Activation"]
    G -->|"Nuclear Translocation"| H["Nuclear Respiratory Factor<br/>Complex Formation"]
    H -->|"Gene Expression"| I["Mitochondrial Biogenesis<br/>Gene Transcription"]
    I -->|"Organelle Formation"| J["Enhanced Mitochondrial<br/>Number and Function"]
    J -->|"Metabolic Shift"| K["Oxidative Phosphorylation<br/>Upregulation"]
    K -->|"Energy Production"| L["ATP Synthesis<br/>Enhancement"]
    L -->|"Metabolic Support"| M["Astrocytic Lactate<br/>Production"]
    M -->|"Neuronal Fuel"| N["Neuronal Energy<br/>Supply"]
    N -->|"Neuroprotection"| O["Reduced Oxidative<br/>Stress"]
    O -->|"Cellular Health"| P["Neuronal Survival<br/>Enhancement"]
    P -->|"Disease Prevention"| Q["Neurodegeneration<br/>Protection"]
    B -->|"Alternative Pathway"| R["CREB Phosphorylation<br/>and Activation"]
    R -->|"Gene Regulation"| I

    classDef normal fill:#4fc3f7,stroke:#2196f3,color:#0d0d1a
    classDef therapeutic fill:#81c784,stroke:#4caf50,color:#0d0d1a
    classDef pathology fill:#ef5350,stroke:#f44336,color:#0d0d1a
    classDef outcome fill:#ffd54f,stroke:#ff9800,color:#0d0d1a
    classDef molecular fill:#ce93d8,stroke:#9c27b0,color:#0d0d1a

    class A,M,N normal
    class B,F,G,R therapeutic
    class Q pathology
    class P,O outcome
    class C,D,E,H,I,J,K,L molecular

⚖️ Evidence

⚖️ Evidence Matrix14 supports9 contradicts

Supports

Astrocytic adenosine signaling is disrupted in neurodegeneration, leading to sleep-wake imbalances

Science2019PMID:30679341medium

Abstract

Species richness of marine mammals and birds is highest in cold, temperate seas-a conspicuous exception to the general latitudinal gradient of decreasing diversity from the tropics to the poles. We compiled a comprehensive dataset for 998 species of sharks, fish, reptiles, mammals, and birds to identify and quantify inverse latitudinal gradients in diversity, and derived a theory to explain these patterns. We found that richness, phylogenetic diversity, and abundance of marine predators diverge systematically with thermoregulatory strategy and water temperature, reflecting metabolic differences between endotherms and ectotherms that drive trophic and competitive interactions. Spatial patterns of foraging support theoretical predictions, with total prey consumption by mammals increasing by a factor of 80 from the equator to the poles after controlling for productivity.

Supports

A2A receptor activation promotes astrocytic glycogen breakdown and lactate production for neuronal support

J Neurosci2015PMID:25904789medium

Abstract

Hair cells of the inner ear are essential for hearing and balance. As a consequence, pathogenic variants in genes specifically expressed in hair cells often cause hereditary deafness. Hair cells are few in number and not easily isolated from the adjacent supporting cells, so the biochemistry and molecular biology of hair cells can be difficult to study. To study gene expression in hair cells, we developed a protocol for hair cell isolation by FACS. With nearly pure hair cells and surrounding cells, from cochlea and utricle and from E16 to P7, we performed a comprehensive cell type-specific RNA-Seq study of gene expression during mouse inner ear development. Expression profiling revealed new hair cell genes with distinct expression patterns: some are specific for vestibular hair cells, others for cochlear hair cells, and some are expressed just before or after maturation of mechanosensitivity. We found that many of the known hereditary deafness genes are much more highly expressed in ha

Supports

Sleep deprivation alters astrocytic adenosine metabolism and impairs neuronal energy supply

PLoS Comput Biol2012PMID:23300412medium

Abstract

Differences between individual human genomes, or between human and cancer genomes, range in scale from single nucleotide variants (SNVs) through intermediate and large-scale duplications, deletions, and rearrangements of genomic segments. The latter class, called structural variants (SVs), have received considerable attention in the past several years as they are a previously under appreciated source of variation in human genomes. Much of this recent attention is the result of the availability of higher-resolution technologies for measuring these variants, including both microarray-based techniques, and more recently, high-throughput DNA sequencing. We describe the genomic technologies and computational techniques currently used to measure SVs, focusing on applications in human and cancer genomics.

Supports

Sepsis expands a CD39(+) plasmablast population that promotes immunosuppression via adenosine-mediated inhibition of macrophage antimicrobial activity.

Immunity2021PMID:34473957medium

Abstract

Sepsis results in elevated adenosine in circulation. Extracellular adenosine triggers immunosuppressive signaling via the A2a receptor (A2aR). Sepsis survivors develop persistent immunosuppression with increased risk of recurrent infections. We utilized the cecal ligation and puncture (CLP) model of sepsis and subsequent infection to assess the role of adenosine in post-sepsis immune suppression. A2aR-deficient mice showed improved resistance to post-sepsis infections. Sepsis expanded a subset of CD39hi B cells and elevated extracellular adenosine, which was absent in mice lacking CD39-expressing B cells. Sepsis-surviving B cell-deficient mice were more resistant to secondary infections. Mechanistically, metabolic reprogramming of septic B cells increased production of ATP, which was converted into adenosine by CD39 on plasmablasts. Adenosine signaling via A2aR impaired macrophage bactericidal activity and enhanced interleukin-10 production. Septic individuals exhibited expanded CD39hi

Supports

Endothelial adenosine receptor 2A loss alleviates diabetic vascular calcification by blocking CREB1-SNAI1-driven EndMT.

Pharmacol Res2025PMID:41067595medium

Abstract

Vascular calcification (VC), a common complication associated with diabetes mellitus (DM), substantially increases the risk of cardiovascular diseases and is associated with elevated mortality in individuals with DM. Endothelial-to-mesenchymal transition (EndMT) imparts phenotypic plasticity to vascular endothelial cells (VECs), granting them the potential for osteogenic differentiation, which is a crucial mechanism in regulating VC. Notably, adenosine-ADORA2A-mediated endothelial dysfunction plays a pivotal regulatory role in cardiovascular diseases. However, the specific role of endothelial ADORA2A in diabetic VC remains to be elucidated. In this study, we found that ADORA2A was upregulated in the endothelium of diabetic mice and cultured human aortic endothelial cells (HAECs) with high glucose treatment. Deletion of endothelial Adora2a or pharmacologic inhibition of ADORA2A with KW6002 attenuated EndMT, osteogenic differentiation, and calcium deposit in diabetic aortas of Ins2Akita/

Supports

Targeting adenosine 2A receptor signaling suppresses vascular calcification by restraining smooth muscle osteogenic differentiation.

Pharmacol Res2025PMID:41201506medium

Abstract

Vascular calcification (VC) is a major contributor to cardiovascular morbidity and mortality, particularly in patients with chronic kidney disease (CKD). Adenosine 2 A receptor (ADORA2A) is highly expressed in vascular cells and implicated in cardiovascular disease; however, its specific role in VC pathogenesis remains unclear. Here, we investigated the role of ADORA2A using in vitro (vascular smooth muscle cells; VSMCs), ex vivo (mouse aortic rings), and in vivo (5/6th nephrectomy with high phosphate and cholecalciferol) models of VC. The ADORA2A expression was significantly upregulated in calcified human and murine aortic tissues, as well as in VSMCs, under osteogenic conditions. Genetic deletion of Adora2a (global or VSMC-specific) or pharmacological antagonism of ADORA2A markedly attenuated aortic calcification and the expression of osteogenic markers in vivo. Consistent findings were observed in in vitro and ex vivo models. Conversely, ADORA2A overexpression exacerbated the osteog

Supports

Adenosine 2A receptor-dependent activation of AMPK represses T(H)17 cell pathogenicity through epigenetic and metabolic reprogramming.

Sci Signal2025PMID:40986641medium

Abstract

Metabolic reprogramming controls protective and pathogenic T helper 17 (TH17) cell responses. When naïve T cells are differentiated into TH17 cells in vitro, the presence of the cytokine activin A promotes their maturation into a nonpathogenic state. Here, we found that nonpathogenic TH17 cells induced by activin A displayed reduced aerobic glycolysis and increased oxidative phosphorylation (OXPHOS). In response to activin A, signaling through the adenosine A2A receptor (A2AR) and AMP-activated protein kinase (AMPK) enhanced OXPHOS and reprogrammed pathogenic TH17 cells toward nonpathogenic states that did not induce central nervous system autoimmunity in a mouse model of multiple sclerosis. In pathogenic TH17 cells, the transcriptional coactivator p300/CBP-associated factor (PCAF) increased acetylation at histone 3 Lys9 (H3K9ac) of genes involved in aerobic glycolysis and TH17 pathogenic programs. In contrast, in nonpathogenic activin A-treated TH17 cells, AMPK signaling suppressed PC

Supports

Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner.

Nat Commun2023PMID:37291128medium

Abstract

Cancer cell metabolism contributes to the establishment of an immunosuppressive tumor microenvironment. Aberrant expression of CD73, a critical enzyme in ATP metabolism, on the cell surface results in the extracellular accumulation of adenosine, which exhibits direct inhibitory effects on tumor-infiltrating lymphocytes. However, little is known about the influence of CD73 on negative immune regulation-associated signaling molecules and transduction pathways inside tumor cells. This study aims to demonstrate the moonlighting functions of CD73 in immunosuppression in pancreatic cancer, an ideal model characterized by complex crosstalk among cancer metabolism, immune microenvironment, and immunotherapeutic resistance. The synergistic effect of CD73-specific drugs in combination with immune checkpoint blockade is observed in multiple pancreatic cancer models. Cytometry by time-of-flight analysis shows that CD73 inhibition reduces tumor-infiltrating Tregs in pancreatic cancer. Tumor cell-au

Supports

Parthenolide inhibits methamphetamine-induced depressive-like behavior by targeting ADORA2A.

Phytomedicine2026PMID:41795299medium

Abstract

BACKGROUND: Methamphetamine (METH) abuse often results in persistent depressive-like behaviors, while current treatments show limited efficacy. Parthenolide, a natural compound with neuroprotective and anti-inflammatory properties, has shown benefits in several CNS disorders, but its role in METH-induced depression remains unknown. PURPOSE: This study aimed to evaluate whether parthenolide alleviates METH-induced depressive-like behaviors and to identify key brain regions and molecular targets involved. METHODS: Mice were administered METH using a 15-day escalating regimen and treated with parthenolide. Behavioral tests, histopathology, Nissl staining, and c-Fos mapping were conducted to assess neural alterations. Metabolomics and network pharmacology were used to predict targets, followed by molecular docking, dynamics simulations, cellular thermal shift assay, and pharmacological modulation for validation. RESULTS: Parthenolide significantly improved METH-induced depressive-like beha

Supports

De novo purine synthesis reprograms the macrophage inflammatory response and the immune response in sepsis.

Res Sq2026PMID:41756441medium

Abstract

Sepsis is characterized by profound immunometabolic dysregulation, yet the role of purine precursor synthesis in immune reprogramming remains poorly defined. Intracellular purine nucleotides, such as ATP, are generated by de novo synthesis, which assembles purinosomes to build inosine monophosphate (IMP) from small precursors, or by the salvage pathway, which recycles purine bases such as hypoxanthine. Here, we investigated how these pathways regulate macrophage activation and host responses in sepsis. Silencing the de novo purine enzyme glycinamide ribonucleotide transformylase (GART) in LPS-stimulated macrophages induced marked transcriptomic remodeling, suppressing anti-inflammatory mediators, including IL-10 and TIMP-1, while increasing TNF-α. These effects were reversed by hypoxanthine supplementation, indicating rescue through salvage. Similar findings were observed with silencing of phosphoribosyl pyrophosphate amidotransferase (PPAT) or pharmacological GART inhibition with azas

Supports

Surface d-Band Modulation via Biodirected Mineralization Enables Nanoenzymes to Inhibit Radiation-Induced T-Cell Exhaustion and Potentiate Immunoradiotherapy.

ACS Nano2025PMID:41073355medium

Abstract

Immunoradiotherapy (iRT) has emerged as a promising strategy for liver hepatocellular carcinoma (LIHC) treatment to synergistically activate both localized antitumor immunity and systemic immune responses. However, radiation will aggravate LIHC hypoxia, resulting in an adenosine metabolism level elevation, which promotes the differentiation of T cells into terminally exhausted phenotypes and weakens the efficacy of immunotherapy. To overcome this challenge, we engineered a nanocatalytic probiotic-based radiation-metabolic modulator, in which Escherichia coli Nissle 1917 (EcN) was programmed to in situ synthesize gold-palladium bimetallic nanocatalysts (EcNcGP) via biodirected mineralization. Guided by lattice mismatch and interfacial strain engineering, engineered EcN orchestrates the epitaxial assembly of Au atoms on Pd nanoclusters, yielding a precisely strain-tuned heterostructure with a modulated d-band electronic structure. This architectural design optimizes oxygen intermediate a

Supports

Research demonstrates inhibition of retinal AdoRA2a activity, which aligns with the hypothesis's focus on ADORA2A receptor modulation.

Invest Ophthalmol Vis Sci2026PMID:41533917medium

Abstract

Although 7-methylxanthine, a nonselective adenosine receptor (AdoRs) antagonist, suppresses myopia, the specific receptor subtype and target tissue involved remain unclear. This study aimed to investigate whether the AdoRA2a subtype plays a critical role in the regulation of myopia progression. Monocular form deprivation myopia (FDM) was induced in mice to measure retinal concentrations of adenosine and its synthetic enzymes (CD39/CD73). Retina-specific AdoRA2a knockout (AdoRA2a-CKO) mice and th

Supports

High-throughput screening for antidepressants targeting adenosine A(2A) receptors directly supports the hypothesis's molecular mechanism.

Bioorg Chem2026PMID:41762553medium

Abstract

The adenosine A2A receptor (A2AR) is a promising therapeutic target for depression, as evidenced by the notable antidepressant-like efficacy of its antagonists. However, conventional screening methods for A2AR ligands are hampered by low throughput and operational complexity. To address this, we developed a high-throughput screening (HTS) strategy based on the detection of calcium flow fluorescence signals in engineered HEK-ADORA2A cells. After rigorous optimization, this HTS platform was deploy

Supports

Explores caffeine's mechanisms of action involving adenosine receptors, which relates to the hypothesis's molecular pathway.

Nutrients2026PMID:41599866medium

Abstract

Ergogenic aids have long attracted scientific interest for their potential to enhance neuromuscular performance, with caffeine being among the most extensively studied. While traditionally attributed to peripheral actions on skeletal muscle, accumulating evidence indicates that, at physiological doses, caffeine's ergogenic effects are predominantly mediated by antagonism of central adenosine receptors. This antagonism leads to increased arousal, reduced inhibitory neuromodulation, enhanced corti

Contradicts

A2A activation promotes inflammation in some contexts while being anti-inflammatory in others

Environ Sci Technol2017PMID:28224793medium

Abstract

More than 3000 per- and polyfluoroalkyl substances (PFASs) are, or have been, on the global market, yet most research and regulation continues to focus on a limited selection of rather well-known long-chain PFASs, particularly perfluorooctanesulfonate (PFOS), perfluorooctanoic acid (PFOA) and their precursors. Continuing to overlook the vast majority of other PFASs is a major concern for society. We provide recommendations for how to proceed with research and cooperation to tackle the vast number of PFASs on the market and in the environment.

Contradicts

A2A receptor antagonists (like caffeine) improve cognitive function and reduce AD risk

J Alzheimers Dis2010PMID:20164566medium

Abstract

Caffeine causes most of its biological effects via antagonizing all types of adenosine receptors (ARs): A1, A2A, A3, and A2B and, as does adenosine, exerts effects on neurons and glial cells of all brain areas. In consequence, caffeine, when acting as an AR antagonist, is doing the opposite of activation of adenosine receptors due to removal of endogenous adenosinergic tonus. Besides AR antagonism, xanthines, including caffeine, have other biological actions: they inhibit phosphodiesterases (PDEs) (e.g., PDE1, PDE4, PDE5), promote calcium release from intracellular stores, and interfere with GABA-A receptors. Caffeine, through antagonism of ARs, affects brain functions such as sleep, cognition, learning, and memory, and modifies brain dysfunctions and diseases: Alzheimer's disease, Parkinson's disease, Huntington's disease, Epilepsy, Pain/Migraine, Depression, Schizophrenia. In conclusion, targeting approaches that involve ARs will enhance the possibilities to correct brain dysfunction

Contradicts

Excessive astrocytic activation can be neurotoxic regardless of energy provision

Science2019PMID:31488706medium

Abstract

Caenorhabditis elegans is an animal with few cells but a wide diversity of cell types. In this study, we characterize the molecular basis for their specification by profiling the transcriptomes of 86,024 single embryonic cells. We identify 502 terminal and preterminal cell types, mapping most single-cell transcriptomes to their exact position in C. elegans' invariant lineage. Using these annotations, we find that (i) the correlation between a cell's lineage and its transcriptome increases from middle to late gastrulation, then falls substantially as cells in the nervous system and pharynx adopt their terminal fates; (ii) multilineage priming contributes to the differentiation of sister cells at dozens of lineage branches; and (iii) most distinct lineages that produce the same anatomical cell type converge to a homogenous transcriptomic state.

Contradicts

Chronic A2A modulation leads to receptor desensitization

J Neurosci2015PMID:25904789medium

Abstract

Hair cells of the inner ear are essential for hearing and balance. As a consequence, pathogenic variants in genes specifically expressed in hair cells often cause hereditary deafness. Hair cells are few in number and not easily isolated from the adjacent supporting cells, so the biochemistry and molecular biology of hair cells can be difficult to study. To study gene expression in hair cells, we developed a protocol for hair cell isolation by FACS. With nearly pure hair cells and surrounding cells, from cochlea and utricle and from E16 to P7, we performed a comprehensive cell type-specific RNA-Seq study of gene expression during mouse inner ear development. Expression profiling revealed new hair cell genes with distinct expression patterns: some are specific for vestibular hair cells, others for cochlear hair cells, and some are expressed just before or after maturation of mechanosensitivity. We found that many of the known hereditary deafness genes are much more highly expressed in ha

Contradicts

Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors

Cancer Lett2021PMID:33845122medium

Abstract

Accumulating evidence suggests that the intestinal microbiota is associated with the antitumor efficacy of immune checkpoint inhibitors (ICIs) and the occurrence of immune-related adverse events (irAEs) following ICI treatment. However, the mechanisms underlying these interactions remain unclear. Recent technological advances have allowed more extensive investigation into the interplay between the intestinal microbiota and the tumor immune microenvironment. Breakthroughs by two research groups revealed that Bifidobacterium enhanced the efficacy of ICIs via the stimulator of interferon genes (STING) and adenosine 2A receptor (A2AR) signaling pathways, highlighting the molecular mechanisms through which the intestinal microbiota modulates immunotherapy. In this review, we summarize recent findings related to the potential role and mechanisms of the gut microbiota in ICI therapy, available microbiota-targeting strategies, and ongoing clinical trials. Further we discuss the associated chal

Contradicts

Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol

Pharmacogenomics J2017PMID:26644204medium

Abstract

Drug-related toxicities represent an important clinical concern in chemotherapy, genetic variants could help tailoring treatment to patient. A pharmacogenetic multicentric study was performed on 508 pediatric acute lymphoblastic leukemia patients treated with AIEOP-BFM 2000 protocol: 28 variants were genotyped by VeraCode and Taqman technologies, deletions of GST-M1 and GST-T1 by multiplex PCR. Toxicities were derived from a central database: 251 patients (49.4%) experienced at least one gastroi

Contradicts

Cord blood gene expression supports that prenatal exposure to perfluoroalkyl substances causes depressed immune functionality in early childhood

J Immunotoxicol2016PMID:25812627medium

Abstract

Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are a class of synthetic compounds that have widespread use in consumer and industrial applications. PFAS are considered environmental pollutants that have various toxic properties, including effects on the immune system. Recent human studies indicate that prenatal exposure to PFAS leads to suppressed immune responses in early childhood. In this study, data from the Norwegian BraMat cohort was used to investigate transcriptomics profiles in ne

Contradicts

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

Clin Pharmacokinet1997PMID:9160173medium

Abstract

Hypercholesterolaemia plays a crucial role in the development of atherosclerotic diseases in general and coronary heart disease in particular. The risk of progression of the atherosclerotic process to coronary heart disease increases progressively with increasing levels of total serum cholesterol or low density lipoprotein (LDL) cholesterol at both the individual and the population level. The statins are reversible inhibitors of the microsomal enzyme HMG-CoA reductase, which converts HMG-CoA to

Contradicts

The integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs

PLoS One2019PMID:30605479medium

Abstract

Safety pharmacology screening against a wide range of unintended vital targets using in vitro assays is crucial to understand off-target interactions with drug candidates. With the increasing demand for in vitro assays, ligand- and structure-based virtual screening approaches have been evaluated for potential utilization in safety profiling. Although ligand based approaches have been actively applied in retrospective analysis or prospectively within well-defined chemical space during the early d

📖 Linked Papers (19)Export BibTeX ↗

A lineage-resolved molecular atlas of C. elegans embryogenesis at single-cell resolution.

Science (2019) · PubMed:31488706 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

The integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs.

PloS one (2019) · PubMed:30605479 ↗

7 figures

Fig 1

Workflow illustration for pharmacophore-based 3D QSAR modeling and virtual screening to identify compounds with antagonistic activities against A2A.

Fig 2

The heat map demonstration for binary fingerprint similarities between training 1 and test 1 (A), training 2 and test 2 (B), the 55 representations of the 268 c...

A Never-Ending Story of Per- and Polyfluoroalkyl Substances (PFASs)?

Environ Sci Technol (2017) · PubMed:28224793 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.

The pharmacogenomics journal (2017) · PubMed:26644204 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Cord blood gene expression supports that prenatal exposure to perfluoroalkyl substances causes depressed immune functionality in early childhood.

Journal of immunotoxicology (2016) · PubMed:25812627 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Gene Expression by Mouse Inner Ear Hair Cells during Development.

J Neurosci (2015) · PubMed:25904789 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Caffeine and adenosine.

J Alzheimers Dis (2010) · PubMed:20164566 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Parthenolide inhibits methamphetamine-induced depressive-like behavior by targeting ADORA2A.

Phytomedicine : international journal of phytotherapy and phytopharmacology (2026) · PubMed:41795299 ↗

No figures

De novo purine synthesis reprograms the macrophage inflammatory response and the immune response in sepsis.

Research square (2026) · PubMed:41756441 ↗

No figures

Targeting adenosine 2A receptor signaling suppresses vascular calcification by restraining smooth muscle osteogenic differentiation.

Pharmacological research (2025) · PubMed:41201506 ↗

No figures

Surface d-Band Modulation via Biodirected Mineralization Enables Nanoenzymes to Inhibit Radiation-Induced T-Cell Exhaustion and Potentiate Immunoradiotherapy.

ACS nano (2025) · PubMed:41073355 ↗

No figures

Endothelial adenosine receptor 2A loss alleviates diabetic vascular calcification by blocking CREB1-SNAI1-driven EndMT.

Pharmacological research (2025) · PubMed:41067595 ↗

No figures

📙 Related Wiki Pages (15)

Autophagy Enhancement for Tauopathytherapeutic Autophagy Enhancers for PDtherapeutic ADORA2A Genegene TGF-β Activator Therapy for Neurodegeneridea Epigenetic Dysregulation in Neurodegenermechanism AAV Capsid Engineering for CNS-Targeted idea Computational Drug Discovery in Neurodegmechanism Ribonuclease κ and Circular RNAs: A New mechanism Tunneling Nanotubes in Neurodegenerationmechanism GSK3 Beta in Neurodegenerationmechanism Hippocampal Granule Cells in Neurodegenecell Parabrachial Nucleus in Neurodegeneratiocell Globus Pallidus Externus GABAergic in Necell BDNF Signaling Pathway in Neurodegeneratmechanism Microglial Priming and Innate Immune Toltherapeutic

🏥 Translation

🧬 3D Protein Structure — ADORA2A

🧬 PDB 4EIY Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for ADORA2A from GTEx v10.

💉 Clinical Trials (10)Relevance: 53%

0
Active

0
Completed

932
Total Enrolled

PHASE1
Highest Phase

A Phase II Trial of Regadenoson in Sickle Cell AnemiaPHASE2

COMPLETED·NCT01788631 · Dana-Farber Cancer Institute

100 enrolled · 2013-07 · → 2016-11-10

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug called Regadenoson (or Lexiscan) to learn whether the drug works in treating a spe

Sickle Cell Anemia

Regadenoson Placebo

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck CancersPHASE1

WITHDRAWN·NCT04892875 · Jennifer Choe

2023-12-31 · → 2025-12

The purpose of this study is to test the safety and tolerability of chemotherapy and radiation in combination with the investigational study drugs zimberelimab (AB122) and etrumadenant (AB928) in subj

Head and Neck Cancer Squamous Cell Carcinoma of Head and Neck Oral Cavity Squamous Cell Carcinoma

Zimberelimab Etrumadenant Cisplatin

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersPHASE1

COMPLETED·NCT02655822 · Corvus Pharmaceuticals, Inc.

502 enrolled · 2016-01 · → 2021-06

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. T

Renal Cell Cancer Metastatic Castration Resistant Prostate Cancer

Ciforadenant Ciforadenant Ciforadenant

A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid TumorsEARLY_PHASE1

ACTIVE_NOT_RECRUITING·NCT06736275 · Jiangsu Nutai Biologics Co., Ltd

8 enrolled · 2024-09-02 · → 2026-02-28

The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.

Advanced Cancer Cachexia

SXRN

Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord InjuryPHASE1

NOT_YET_RECRUITING·NCT05217498 · Randy Trumbower, PT, PhD

40 enrolled · 2027-09-01 · → 2027-12-30

Breathing brief, moderate bouts of low oxygen trigger (low oxygen therapy, LOT) spinal plasticity (the ability of the nervous system to strengthen neural pathways based on new experiences), and improv

Spinal Cord Injuries Myelopathy

Istradefylline low oxygen therapy

RAPA-501 Therapy for ALSPHASE2

RECRUITING·NCT04220190 · Rapa Therapeutics LLC

41 enrolled · 2025-01-02 · → 2026-07-01

RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

Amyotrophic Lateral Sclerosis

RAPA-501 Autologous T stem cells

MAD Phase I Study to Investigate Contraloid AcetatePHASE1

COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold

24 enrolled · 2018-12-12 · → 2019-04-03

This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a

Alzheimer Dementia Alzheimer Disease

Contraloid

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain InjuryN/A

UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center

60 enrolled · 2021-10-01 · → 2024-09

This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu

Neurodegenerative Diseases

Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1

NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.

12 enrolled · 2026-02-28 · → 2027-12-15

Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p

Parkinson Disease

ALC01 therapy

MRI Biomarkers in ALSN/A

COMPLETED·NCT02405182 · University of Alberta

145 enrolled · 2014-09 · → 2019-03

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f

Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases

Magnetic Resonance Imaging

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for ADORA2A →

No DepMap CRISPR Chronos data found for ADORA2A.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

18 months

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↘

Falling

7d Momentum

▼ 2.7%

Volatility

Low

0.0052

Events (7d)

6

Price History

▼24.6%

💾 Resource Usage

LLM Tokens

17,678

$0.1061

Total Cost

$0.1061

🔮 Predictions

🔎 Predictions vs Observations21 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
Selective AQP4 upregulation without sleep improvement in transgenic models	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Glymphatic enhancement in awake states showing equal clearance benefits	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Long-term AQP4 modulation studies showing no cognitive protection	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
OR2 agonist treatment worsening sleep quality despite microglial changes	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Orexin enhancement accelerating rather than slowing neurodegeneration	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Microglial depletion preventing orexin-mediated benefits	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
A2A antagonists providing superior cognitive protection than agonists	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Metabolic enhancement without sleep improvement showing no neuroprotection	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Adenosine system manipulation having no effect on established neurodegeneration	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
α2A agonists accelerating cognitive decline despite reducing tau pathology	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
LC lesions preventing rather than promoting tau spread	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
REM enhancement having no effect on established tau networks	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Circadian restoration without autophagy enhancement showing no benefits	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Autophagy enhancement in circadian-disrupted models providing full protection	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Clock gene manipulation worsening neurodegeneration despite improved autophagy	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Sleep spindle enhancement without memory improvement in MCI patients	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
T-type channel modulation causing seizures or cardiac arrhythmias	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Spindle-independent memory consolidation pathways providing equal benefits	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Neurogenesis enhancement without cognitive benefits in human studies	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
Hypocretin modulation disrupting rather than improving sleep architecture	Confirmatory evidence for hypothesis	— no observation —	pending	0.65
BDNF manipulation causing adverse neurological effects	Confirmatory evidence for hypothesis	— no observation —	pending	0.65

🔮 Falsifiable Predictions (10)

pendingconf 65%

Glymphatic enhancement in awake states showing equal clearance benefits